Article citationsMore>>

Xie, J., Jang, A., Vegel, A., Hajja, Y., Mouawad, Y., Baghian, A., Berbari, B., Schmid, J.L., Socola, F., Safah, H. and Saba, N.S. (2021) Successful Treatment of “Accelerated” Chronic Lymphocytic Leukemia with Single Agent Ibrutinib: A Report of Two Cases. Leukemia Research Reports, 15, Article ID: 100247.
https://doi.org/10.1016/j.lrr.2021.100247

has been cited by the following article:

• TITLE: A Rare Entity of Accelerated Chronic Lymphocytic Leukemia: A Report of Two Cases and Review of Literature

  AUTHORS: Zahra Kmira, Ben Yahya Noura, Chembah Wafa, Ben Sayed Nesrine, Chiba Dorra, Bouteraa Walid, Zaier Monia, Ben Youssef Yosra, Haifa Regaieg, Khelif Abderrahim

  KEYWORDS: Accelerated Chronic Lymphocytic Leukemia, Richter Transformation, Prognosis, Treatment

  JOURNAL NAME: Health, Vol.15 No.8, August 22, 2023

  ABSTRACT: Background: Accelerated-chronic lymphocytic leukemia (A-CLL) is a rare disease entity as it represents less than 1% of all reported cases of chronic lymphoid leukemia (CLL). Moreover, it is most likely an under diagnosed entity due to its rarity and the non-standardized practice of lymph node biopsy in CLL. Purpose: The aims of our work are to establish the diagnosis of A-CLL and to study the prognosis and treatment of this rare entity. Method: here, we report the clinical presentation and the follow up of two cases of A-CLL. Results: Distinguishing Richter transformation (RT) from A-CLL is important as it may result in a major change in disease management. The prognosis of A-CLL is intermediate between CLL and RT. The prognosis is mainly poor due to a predominance of poor prognostic markers including an increasing number of p53-positive cases. Conclusion: To this date, no prospective study has been led to define the best treatment for A-CLL. The shorter survival of A-CLL when compared to typical CLL implies the need of a more aggressive treatment.